Reports Search Total = 3

Latin America Diabetes Drugs Market – Growth, Trends and Forecast (2019 – 2024)

Healthcare Published by: Mordor Intelligence Market: South America
80 pages Published: 22-07-2019
  • Healthcare
  • Mordor Intelligence
  • South America
  • 80 pages
  • Published: 22-07-2019

Market Overview

 

– The market for LATAM diabetes Drugs Market is USD 3.5 billion in 2017 and is expected to witness an approximate CAGR of 5% during the forecast period, primarily due to the growing geriatric population. 

– The diabetic prevalence is high in the countries in the Latin American region, and Mexico is known to have a high number of diabetic patients due to the growing type 2 population in the country. 

– The gradually growing obesity rate combined with the genetic predisposition for Type 2 diabetes is acting as a prominent driver for the increase in type two diabetic population over the last 40 years. 

– Now close to 10% of the total population are living with diabetes in one form or the other.  The diabetic patients in the LATAM region majorly type 2 patients that account for close to 90% of the total diabetic population in 2017.  

 

Scope of the Report

 

The Market is segmented by category (insulin, oral anti-diabetic drugs, non-insulin injectable drugs, and combination drugs), by segment (basal or long-acting, bolus or fast-acting, traditional human insulin drugs, insulin biosimilars, GLP-1 receptor agonists, alpha-glucosidase inhibitors, DPP-4 inhibitors, and SGLT-2 inhibitors), and by geography.

 

Key Market Trends

 

Oral diabetic drug has high sales

 

– Type 2 oral diabetic drug has high sales in this region mainly due to the low-cost factor.

– Most of the drugs are generic and so are priced way lower than branded drugs.

– Biguanides are considered to be the first class of oral drugs for type 2 patients.

– Mexico is among the top 10 countries that have the highest market value and volume for Biguanides.

– The market for the generic diabetic drug has a high potential for future growth in various countries in the LATAM region.

 

Brazil accounts for the highest market share in Latin Ameria diabetes drugs market

 

– Brazil accounts for 51% of the diabetic drug market in LATAM. In 2017, mainly due to higher consumption of insulin by type 1 patients.

– Brazil accounts for close to 78% of all the type 1 patients in the region. Basal insulin Lantus accounts for the largest share by value of 89% in 2017 in the Brazil insulin market.

 

Competitive Landscape

 

– Novo Nordisk holds the highest market share in the Latin America diabetes drug market.

– Branded drugs of Eli Lilly & Boehringer Ingelheim Alliance is expected grow with the high CAGR of more than 15% in the forecast period

 

Reasons to Purchase this report:

– The market estimate (ME) sheet in Excel format

– Report customization as per the client’s requirements

– 3 months of analyst support

1 INTRODUCTION

1.1 Study Deliverables

1.2 Study Assumptions

1.3 Scope of the Study

2 RESEARCH METHODOLOGY

3 EXECUTIVE SUMMARY

4 MARKET DYNAMICS

4.1 Market Overview

4.2 Drivers

4.3 Restraints

4.4 Porter’s Five Forces Analysis

4.4.1 Bargaining Power of Suppliers

4.4.2 Bargaining Power of Consumers

4.4.3 Threat of New Entrants

4.4.4 Threat of Substitute Products and Services

4.4.5 Intensity of Competitive Rivalry

5 MARKET SEGMENTATION

5.1 BY Drug

5.1.1 Oral anti-diabetic drugs

5.1.1.1 Biguanide (Value and Volume 2012-2024)

5.1.1.1.1 Metformin

5.1.1.2 Alpha – Glucosidase inhibitors (Value and Volume 2012-2024)

5.1.1.2.1 Alpha – Glucosidase inhibitors

5.1.1.3 Sodium – glucose cotransport -2 (SGLT-2) inhibitor (Value and Volume 2012-2024)

5.1.1.3.1 Invokana (Canagliflozin)

5.1.1.3.2 Jardiance (Empagliflozin)

5.1.1.3.3 Farxiga/Forxiga (Dapagliflozin)

5.1.1.3.4 Suglat (Ipragliflozin)

5.1.1.4 Dipeptidyl peptidase – 4 (DPP-4) inhibitors (Value and Volume 2012-2024)

5.1.1.4.1 Januvia (Sitagliptin)

5.1.1.4.2 Onglyza (Saxagliptin)

5.1.1.4.3 Tradjenta (Linagliptin)

5.1.1.4.4 Vipidia/Nesina (Alogliptin)

5.1.1.4.5 Galvus (Vildagliptin)

5.1.1.5 Sulfonylureas (Value and Volume 2012-2024)

5.1.1.5.1 Sulfonylureas

5.1.1.6 Meglitinide (Value and Volume 2012-2024)

5.1.1.6.1 Meglitinide

5.1.2 Insulin

5.1.2.1 Basal or Long Acting Insulins

5.1.2.1.1 Lantus (Insulin Glargine)

5.1.2.1.2 Levemir (Insulin Detemir)

5.1.2.1.3 Toujeo (Insulin Glargine)

5.1.2.1.4 Tresiba (Insulin Degludec)

5.1.2.1.5 Basaglar (Insulin Glargine)

5.1.2.2 Bolus or Fast Acting Insulins

5.1.2.2.1 NovoRapid/Novolog (Insulin Aspart)

5.1.2.2.2 Humalog (Insulin Lispro)

5.1.2.2.3 Apidra (Insulin Glulisine)

5.1.2.3 Traditional Human Insulins

5.1.2.3.1 Novolin/Actrapid/Insulatard

5.1.2.3.2 Humilin

5.1.2.3.3 Insuman

5.1.2.4 Biosimilar Insulins

5.1.2.4.1 Insulin Glargine Biosimilars

5.1.2.4.2 Human Insulin Biosimilars

5.1.3 Non-Insulin Injectable drugs

5.1.3.1 GLP1 receptor agonists

5.1.3.1.1 Victoza (Liraglutide)

5.1.3.1.2 Byetta (Exenatide)

5.1.3.1.3 Bydureon (Exenatide)

5.1.3.1.4 Trulicity (Dulaglutide)

5.1.3.1.5 Lyxumia (Lixisenatide)

5.1.4 Combination Drugs

5.1.4.1 Insulin Combinations

5.1.4.1.1 NovoMix (Biphasic Insulin Aspart)

5.1.4.1.2 Ryzodeg (Insulin Degludec and Insulin Aspart)

5.1.4.1.3 Xultophy (Insulin Degludec and Liraglutide)

5.1.4.2 Oral Combination

5.1.4.2.1 Janumet (Sitagliptin and Metformin HCl)

5.2 Geography

5.2.1 Latin America

5.2.1.1 Brazil (Value and Volume 2012-2024)

5.2.1.1.1 Oral Anti-diabetic Drugs

5.2.1.1.2 Insulin

5.2.1.1.3 Non-Insulin Injectable Drugs

5.2.1.1.4 Combination Drugs

5.2.1.1.5 By Company (Novo Nordisk, Sanofi, Eli Lilly, AstraZeneca, Astellas, Janssen, Merck and others)

5.2.1.2 Mexico (Value and Volume 2012-2024)

5.2.1.2.1 Oral Anti-diabetic Drugs

5.2.1.2.2 Insulin

5.2.1.2.3 Non-Insulin Injectable Drugs

5.2.1.2.4 Combination Drugs

5.2.1.2.5 By Company (Novo Nordisk, Sanofi, Eli Lilly, AstraZeneca, Astellas, Janssen, Merck and others)

5.2.1.3 Rest of Latin America (Value and Volume 2012-2024)

5.2.1.3.1 Oral Anti-diabetic Drugs

5.2.1.3.2 Insulin

5.2.1.3.3 Non-Insulin Injectable Drugs

5.2.1.3.4 Combination Drugs

5.2.1.3.5 By Company (Novo Nordisk, Sanofi, Eli Lilly, AstraZeneca, Astellas, Janssen, Merck and others)

6 MARKET INDICATORS

6.1 Type-1 Diabetes population (2012-2024)

6.2 Type-2 Diabetes population (2012-2024)

7 COMPETITIVE LANDSCAPE

7.1 Company Profiles

7.1.1 Takeda

7.1.2 Pfizer

7.1.3 Eli Lilly

7.1.4 Janssen Pharmaceuticals

7.1.5 Astellas

7.1.6 Boehringer Ingelheim

7.1.7 Merck And Co.

7.1.8 AstraZeneca

7.1.9 Bristol Myers Squibb

7.1.10 Novartis

7.1.11 Sanofi

7.1.12 Novo Nordisk

8 MARKET OPPORTUNITIES AND FUTURE TRENDS

MARKET SEGMENTATION

 

BY Drug

Oral anti-diabetic drugs

Biguanide (Value and Volume 2012-2024)

Metformin

Alpha – Glucosidase inhibitors (Value and Volume 2012-2024)

Alpha – Glucosidase inhibitors

Sodium – glucose cotransport -2 (SGLT-2) inhibitor (Value and Volume 2012-2024)

Invokana (Canagliflozin)

Jardiance (Empagliflozin)

Farxiga/Forxiga (Dapagliflozin)

Suglat (Ipragliflozin)

Dipeptidyl peptidase – 4 (DPP-4) inhibitors (Value and Volume 2012-2024)

Januvia (Sitagliptin)

Onglyza (Saxagliptin)

Tradjenta (Linagliptin)

Vipidia/Nesina (Alogliptin)

Galvus (Vildagliptin)

Sulfonylureas (Value and Volume 2012-2024)

Sulfonylureas

Meglitinide (Value and Volume 2012-2024)

Meglitinide

Insulin

Basal or Long Acting Insulins

Lantus (Insulin Glargine)

Levemir (Insulin Detemir)

Toujeo (Insulin Glargine)

Tresiba (Insulin Degludec)

Basaglar (Insulin Glargine)

Bolus or Fast Acting Insulins

NovoRapid/Novolog (Insulin Aspart)

Humalog (Insulin Lispro)

Apidra (Insulin Glulisine)

Traditional Human Insulins

Novolin/Actrapid/Insulatard

Humilin

Insuman

Biosimilar Insulins

Insulin Glargine Biosimilars

Human Insulin Biosimilars

Non-Insulin Injectable drugs

GLP1 receptor agonists

Victoza (Liraglutide)

Byetta (Exenatide)

Bydureon (Exenatide)

Trulicity (Dulaglutide)

Lyxumia (Lixisenatide)

Combination Drugs

Insulin Combinations

NovoMix (Biphasic Insulin Aspart)

Ryzodeg (Insulin Degludec and Insulin Aspart)

Xultophy (Insulin Degludec and Liraglutide)

Oral Combination

Janumet (Sitagliptin and Metformin HCl)

 

Geography

Latin America

Brazil (Value and Volume 2012-2024)

Oral Anti-diabetic Drugs

Insulin

Non-Insulin Injectable Drugs

Combination Drugs

By Company (Novo Nordisk, Sanofi, Eli Lilly, AstraZeneca, Astellas, Janssen, Merck and others)

Mexico (Value and Volume 2012-2024)

Oral Anti-diabetic Drugs

Insulin

Non-Insulin Injectable Drugs

Combination Drugs

By Company (Novo Nordisk, Sanofi, Eli Lilly, AstraZeneca, Astellas, Janssen, Merck and others)

Rest of Latin America (Value and Volume 2012-2024)

Oral Anti-diabetic Drugs

Insulin

Non-Insulin Injectable Drugs

Combination Drugs

By Company (Novo Nordisk, Sanofi, Eli Lilly, AstraZeneca, Astellas, Janssen, Merck and others)

We value your investment and offer free customization with every report to fulfil your exact research needs.

Share This Post:

Choose License Type

South America Mammography Market – Growth, Trends, and Forecast (2019 – 2024)

Healthcare Published by: Mordor Intelligence Market: South America
60 pages Published: 16-07-2019
  • Healthcare
  • Mordor Intelligence
  • South America
  • 60 pages
  • Published: 16-07-2019

Market Overview

 

The major factors for the growth of the South American mammography market include the rising incidences of breast cancer, research, and development in the field of breast cancer therapies, and advancements in the technologies of breast imaging modalities.

 

 

– The rising incidence of breast cancer in the region is expected to drive the overall growth of the market over the forecast period.

 

 

– According to the estimates of the American Cancer Society, in Latin America and the Caribbean, around 1.1 million new cancer cases and 600,000 cancer deaths are estimated to occur annually.

 

 

– Breast cancer is the leading cause of cancer death, with about 43,000 deaths annually in Latin America and the Caribbean. The prevalence of breast cancer is rising in South America, owing to the increased prevalence of hormonally-linked factors, such as delayed childbearing and lower parity, as well as lifestyle risk factors. The rising cases of breast cancer may create a huge demand for safe and accurate diagnosis of the disease. Furthermore, most of the market players are focusing on the technological advancements of the products. Thus, owing to the rising cases of breast cancer, the South American mammography market is expected to witness high growth over the forecast period.

 

 

Scope of the Report

 

As per the scope of the report, mammography equipment refers to a standard diagnostic and screening technique that is used to screen breast tissues to check the presence of a malignant tumor. The process involves usage of low-energy x-rays for early detection of breast cancer. On the basis of technology used, the mammography market can be classified as film screen or digital one. The South American mammography market is segmented by product, end user, and geography.

 

 

Key Market Trends

 

Digital Mammography Systems Segment is Expected to be the Fastest Growing Segment During the Forecast Period

 

The digital mammography is a specialized and advanced form of mammography that uses digital receptors and computers instead of x-ray films to examine breast tissue for the presence of tumors. So far, conventional screen-film mammography (SFM), with high spatial resolution, has been the preferred choice for screening programs in most countries. However, with the advent of digital mammography, most of the users are shifting toward these new systems, due to their superior depiction of low-contrast objects, wider dynamic change, and improved diagnostic quality of images, especially when examining denser breasts. They also come with an added advantage of soft-copy image displays and soft-copy reading, which can be easily transferred. Thus, digital mammography is becoming the preferred choice of screening, even though the cost of the new technology is six times higher than the conventional systems. Radiation exposure is significantly lower when compared to analog systems. Thus, owing to the all aforementioned factors the market studied is expected to witness high growth rate over the forecast period.

 

Competitive Landscape

 

The South America mammography market is a consolidated market, owing to the presence of a few major players. Most of the market players are focusing on technological developments of mammography equipment. Some of the players, such as Canon Medical Systems Corporation, Fujifilm Corporation, GE Healthcare, Hologic Inc., Koninklijke Philips NV, and Siemens Healthineers, hold significant market share.

 

Reasons to Purchase this report:

– The market estimate (ME) sheet in Excel format
– Report customization as per the client’s requirements
– 3 months of analyst support

1 INTRODUCTION
1.1 Study Deliverables
1.2 Study Assumptions
1.3 Scope of the Study

2 RESEARCH METHODOLOGY

3 EXECUTIVE SUMMARY

4 MARKET DYNAMICS
4.1 Market Overview
4.2 Market Drivers
4.2.1 Rising Incidences of Breast Cancer
4.2.2 Research and Development in the Field of Breast Cancer Therapies
4.2.3 Advancements in the Technologies of Breast Imaging Modalities
4.3 Market Restraints
4.3.1 High Cost of Imaging Systems
4.3.2 Risk of Adverse Effects of Radiation Exposure
4.4 Porter’s Five Forces Analysis
4.4.1 Threat of New Entrants
4.4.2 Bargaining Power of Buyers/Consumers
4.4.3 Bargaining Power of Suppliers
4.4.4 Threat of Substitute Products
4.4.5 Intensity of Competitive Rivalry

5 MARKET SEGMENTATION
5.1 By Product
5.1.1 Digital Mammography Systems
5.1.2 Analog Mammography Systems
5.1.3 Breast Tomosynthesis
5.1.4 Film Screen Mammography Systems
5.1.5 Other Products
5.2 By End User
5.2.1 Hospitals
5.2.2 Specialty Clinics
5.2.3 Diagnostic Centers
5.3 Geography
5.3.1 Brazil
5.3.2 Argentina
5.3.3 Rest of South America

6 COMPETITIVE LANDSCAPE
6.1 Company Profiles
6.1.1 Canon Medical Systems Corporation
6.1.2 Fujifilm Corporation
6.1.3 GE Healthcare
6.1.4 Hologic Inc.
6.1.5 IMS Giotto SPA
6.1.6 Koninklijke Philips NV
6.1.7 Planmed Oy
6.1.8 Siemens Healthineers

7 MARKET OPPORTUNITIES AND FUTURE TRENDS

MARKET SEGMENTATION

 

 

By Product
Digital Mammography Systems
Analog Mammography Systems
Breast Tomosynthesis
Film Screen Mammography Systems
Other Products

 

By End User
Hospitals
Specialty Clinics
Diagnostic Centers

 

Geography
Brazil
Argentina
Rest of South America

 

We value your investment and offer free customization with every report to fulfil your exact research needs.

Share This Post:

Choose License Type

South and Central America Smart Meters Market – Growth Trends and Forecasts (2019 – 2024)

Information & Communications Technology Published by: Mordor Intelligence Market: South America
90 pages Published: 12-06-2019
  • Information & Communications Technology
  • Mordor Intelligence
  • South America
  • 90 pages
  • Published: 12-06-2019

Market Overview

 

The South and Central America Smart Meter Market is expected to register a CAGR of over 21.1% during the forecast period 2019 – 2024. The market is primarily driven by governmental roll-outs for large-scale incorporations, in the absence of which, the primary drivers are theft prevention and reduction of other non-technical loses, along with functionality improvements, such as the ability to control utilities remotely and time-based tariffs. However, countries lacking supporting legislation are witnessing slow growth in the market, with patchy implementation of the technology. This also inhibits these systems from performing at their optimal level.

South & Central America is witnessing a rapid increase in the population migrating to urban cities. Given the rising need to reduce global energy demand by one-third by adopting energy efficient practices, a number of initiatives by the governments are helping promote energy efficiency initiatives across the region.

Deployment of smart grids and smart metering systems provides solutions to curb energy wastage in industries. Implementation of smart metering systems enables energy suppliers to continuously monitor the electricity usage, by employing smart meter systems at multiple points within the grid.

With innovations in technology, new meters with improved efficiency are expected to be employed. Consumers and governments around the world, including energy producers and suppliers, have realized the advantages of employing smart metering systems and are pushing toward their deployment.

The most prominent limitation in the smart metering market is the unavailability of capital funding. Smart systems are comparatively expensive than the regular metering equipment employed by most of service providers and users. Smart metering systems utilize digital components and connectivity systems that enable them to operate and transmit data. This increases the cost of the metering equipment.

Moreover, different smart meters are designed with various parameters, based on the operational requirements and consumer requirements, thus, driving the costs. Furthermore, smart meters are complicated equipment that requires skilled labor. All these factors drive the overall cost of these systems, making them expensive, compared to regular and conventional metering systems.

Scope of the Report

The increasing technological awareness and internet penetration in the developing countries and the growing demand in developed countries for advanced metering infrastructure (AMI) to replace existing AMR systems are expected to result in the growth of the global smart meter market. However, the saturation of the smart electricity meter market segment in major countries, with reducing yearly demand, is expected to pose a major challenge to the market, resulting in a low growth rate.

Smart electricity meters account for the largest share of the market, which is expected to witnesses declining demand throughout the forecast period. This is expected to negatively affect the overall market. It is anticipated to be revived by the large-scale roll-outs. However, smart gas and water meter segments are expected to show consistent growth during the forecast period.

Key Market Trends

 

Electricity is expected to register a Significant Growth

 

Brazil has stringent regulation policies, resulting in a consolidated market. Landis+Gyr and Elster are significant players in the country, providing high barriers for new entrants.

In Mexico, there are possibilities of significant investments that are expected to boost the yearly demand volume from the earlier 0.58 million units to 1.54 million units until 2022. The revenues of the smart meter market are not expected to follow a similar growth rate, as the growing competition is increasing the price pressure on the manufacturers.

Chile has a national rollout planned, which is expected to significantly boost the smart electricity meters market in the country. Whereas their incorporation in Ecuador is expected to be fueled by the need to reduce non-technical losses. However, the progress of the market in these countries is slow. The region at large suffers from a lack of funds, and therefore, any prospect of short-term growth of the Latin American market is absent.

Brazil to hold a Major Share

 

Brazil is a prominent market in Latin America, with leading utility providers like Endesa. The vast consumer base of nearly 5.7 million provides a substantial size of the potential market. The country is planning significant rollouts of smart electricity meters after positive experiences in Italy and Spain. Brazil is expected to witness significant growth in the smart gas meter market. The Brazilian government has announced funding worth around USD 200 million for developments of smart grids and also announced plans to equip smart meters in the whole country by 2021. This factor, coupled with Brazils strong importance on renewable energy generation, is expected to act as a driving factor for the Brazilian smart meter market.

Lack of regulations and funding is a vital issue, which severely restrains the market. However, water scarcity in various parts of the region is acting as a major driver for the utility department to start running trial projects, and if water scarcity continues to deteriorate further, it may accelerate smart meter deployments.

Brazil’s utility holding company AEGEA is expected to aid its subsidiary utility Nascentos do Xingu to deploy event management solutions. This technology is anticipated to be used to better understand water usage patterns for the development of tailored water efficiency initiatives. This also can be used to modernize the country’s distribution system to meet the growing demands of smart water, due to a rapid increase in its customer base.

Competitive Landscape

 

The South and Central America Smart Meter Market is highly competitive and consists of several major players. In terms of market share, few of the major players currently dominate the market. These major players with prominent share in the market are focusing on expanding their customer base across foreign countries. These companies are leveraging on strategic collaborative initiatives to increase their market share and increase their profitability. The companies operating in the market are also acquiring start-ups working on South and Central America Smart Meter technologies to strengthen their product capabilities.

In Sep 2017, Landis+Gyr, a global smart metering supplier with its smart grid solutions, has secured one of the largest smart metering contracts, yet awarded in India, with Tata Power Delhi Distribution Ltd. Encompassing 200,000 single-phase and three-phase smart meters, the project was a follow up to the contract for India’s first Advanced Metering Infrastructure (AMI) with Radio Frequency (RF) Canopy, comprising 500,000 endpoints, which Tata Power-DDL awarded to Landis+Gyr earlier in the year.

Reasons to Purchase this report:

– The market estimate (ME) sheet in Excel format
– Report customization as per the client’s requirements
– 3 months of analyst support

1 INTRODUCTION
1.1 Study Deliverables
1.2 Study Assumptions
1.3 Scope of the Study

2 RESEARCH METHODOLOGY

3 EXECUTIVE SUMMARY

4 MARKET DYNAMICS
4.1 Market Overview
4.2 Introduction to Market Drivers and Restraints
4.3 Market Drivers
4.3.1 Need for Improvement in Energy Efficiency
4.3.2 Billing Accuracy and Customer Convenience
4.4 Market Restraints
4.4.1 High Costs and Security Concerns
4.4.2 Integration Difficulties with Smart Meters
4.5 Value Chain / Supply Chain Analysis
4.6 Industry Attractiveness – Porter’s Five Forces Analysis
4.6.1 Threat of New Entrants
4.6.2 Bargaining Power of Buyers/Consumers
4.6.3 Bargaining Power of Suppliers
4.6.4 Threat of Substitute Products
4.6.5 Intensity of Competitive Rivalry

5 MARKET SEGMENTATION
5.1 By Type
5.1.1 Electricity
5.1.2 Gas
5.1.3 Water
5.2 By End User
5.2.1 Commercial
5.2.2 Industrial
5.2.3 Residential
5.3 Geography
5.3.1 South and Central America
5.3.1.1 Brazil
5.3.1.2 Mexico
5.3.1.3 Argentina
5.3.1.4 Chile
5.3.1.5 Spain
5.3.1.6 Rest of South and Central America

6 COMPETITIVE LANDSCAPE
6.1 Company Profiles
6.1.1 General Electric Co.
6.1.2 Landis+Gyr Group AG
6.1.3 Sensus USA Inc. (Xylem Inc.
6.1.4 Echelon Corporation
6.1.5 Diehl Stiftung & Co. KG
6.1.6 Wasion Group Holdings
6.1.7 Elster Group GmbH (Honeywell)
6.1.8 Kamstrup AS
6.1.9 Itron Inc.
6.1.10 Arad Group
6.1.11 Zenner International GmbH & Co. KG

7 MARKET OPPORTUNITIES AND FUTURE TRENDS
7.1 Investment Analysis

MARKET SEGMENTATION

 

By Type
Electricity
Gas
Water

By End User
Commercial
Industrial
Residential

Geography
South and Central America
Brazil
Mexico
Argentina
Chile
Spain
Rest of South and Central America

We value your investment and offer free customization with every report to fulfil your exact research needs.

Share This Post:

Choose License Type